Managing Director and Chief Executive Officer
Sraman Life Sciences
Dr. Saji George is a veteran pharmaceutical and biotechnology leader with a
distinguished career spanning over three decades in drug discovery,
development, and strategic program management. As the Managing
Director and CEO of Sraman Life Sciences, he leads with a unique vision,
integrating deep domain knowledge with techno-commercial acumen to
guide biotech innovators through the complex terrain of preclinical and
translational research.
Dr. George’s career has traversed the entire drug development lifecycle,
from early discovery screening and lead optimization to GLP toxicology,
clinical development, and commercial scale manufacturing, especially of
fermentation-based molecules. His portfolio includes work on anti-
infectives, anti-cancer new chemical entities (NCEs), and advanced
generics, many
milestones.
At Piramal Life Sciences, Dr. George held a pivotal leadership role,
overseeing beta-lactam antibiotic manufacturing and launching high-
throughput screening platforms for cutting-edge molecules such as
Echinocandin and Flavopiridol. His team also explored the potential of
marine organism-derived NCEs, leading to promising anti-infective and anti-
cancer candidates. At Dr. Reddy’s Laboratories, he was instrumental in
driving business development and strategic partnerships for fermentation-
based generics, playing a key role in developing complex biologics like
Sirolimus and Liraglutide, products that set benchmarks in scale, quality,
and regulatory compliance.
Dr. George’s contributions extend beyond industry. As a Distinguished
Scientist at the Rajiv Gandhi Centre for Biotechnology (RGCB), he also took
on the role of Managing Director of BioNest, a Biotechnology Start up Park,
where he fostered innovation and business development by mentoring over
30 biotech start-ups, providing them with guidance on scientific direction,
compliance, and commercialization strategies.
At Sraman Life Sciences, Dr. George now channels this vast experience into
building a “one stop preclinical consulting and project management
platform”. Under his leadership, the company specializes in Regulatory-
aligned IND-enabling services, Custom design of GLP studies, CRO
coordination across toxicology, bio-analytics, and NHP models as well as
bridging academic innovations with global biotech standards. A passionate
mentor and science strategist, Dr. George is committed to making high-
quality preclinical research faster, leaner, and globally credible, delivering
value not just to sponsors, but to the entire healthcare ecosystem.
